Versartis Inc (VSAR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Versartis Inc (VSAR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7607
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Versartis Inc (Versartis) is a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of endocrine disorders. The company’s lead product candidate include somavaratan (VRS-317) is a recombinant human growth hormone (GHD) that is designed to reduce the burden of daily injection therapy which is used in the treatment of growth hormone deficiency in both children and adults. It utilizes half-life extension technology, a proprietary recombinant polypeptide technology for development of its products. The company serves life science industry. Versartis is headquartered in Menlo Park, California, the US.

Versartis Inc (VSAR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versartis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Versartis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Versartis Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Versartis Raises US$55 Million In Series E Financing 10
Versartis Secures USD12.49 Million in Series C Venture Funding 12
Versartis Raises US$20 Million In Series D Financing 13
Versartis Raises US$25 Million In Series C Financing 15
Licensing Agreements 17
Teijin Pharma Enters into Licensing Agreement with Versartis 17
Equity Offering 19
Versartis Raises USD63.4 Million in Public Offering of Shares 19
Versartis Raises USD86.3 Million in Public Offering of Shares 21
Versartis Completes IPO Of For US$145 Million 23
Versartis Inc – Key Competitors 25
Versartis Inc – Key Employees 26
Versartis Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 07, 2018: Versartis announces second quarter 2018 financial results 28
May 08, 2018: Versartis Reports First Quarter 2018 Financial Results 30
Mar 01, 2018: Versartis Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 31
Oct 26, 2017: Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update 33
Jul 27, 2017: Versartis Reports Second Quarter 2017 Financial Results 34
Apr 27, 2017: Versartis Reports First Quarter 2017 Financial Results 36
Feb 21, 2017: Versartis Reports Fourth Quarter 2016 Financial Results 37
Corporate Communications 39
Sep 05, 2017: Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs 39
Jun 01, 2017: Versartis Appoints Eric Dobmeier to Board of Directors 40
Apr 25, 2017: Versartis Appoints Jay Stout, Ph.D., as Senior Vice President, Technical Operations 41
Mar 15, 2017: Versartis Appoints Tracy Woody as Chief Commercial Officer 42
Jan 31, 2017: Versartis announces management changes 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Versartis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versartis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versartis Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Versartis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Versartis Raises US$55 Million In Series E Financing 10
Versartis Secures USD12.49 Million in Series C Venture Funding 12
Versartis Raises US$20 Million In Series D Financing 13
Versartis Raises US$25 Million In Series C Financing 15
Teijin Pharma Enters into Licensing Agreement with Versartis 17
Versartis Raises USD63.4 Million in Public Offering of Shares 19
Versartis Raises USD86.3 Million in Public Offering of Shares 21
Versartis Completes IPO Of For US$145 Million 23
Versartis Inc, Key Competitors 25
Versartis Inc, Key Employees 26
Versartis Inc, Subsidiaries 27

List of Figures
Versartis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versartis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Versartis Inc (VSAR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BYD Company Limited:企業の戦略・SWOT・財務分析
    BYD Company Limited - Strategy, SWOT and Corporate Finance Report Summary BYD Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Reliance Communications Limited:企業の戦略・SWOT・財務分析
    Reliance Communications Limited - Strategy, SWOT and Corporate Finance Report Summary Reliance Communications Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • St. Jude Children’s Research Hospital Inc-製薬・医療分野:企業M&A・提携分析
    Summary St. Jude Children’s Research Hospital Inc (St. Jude) is a healthcare service provider that offers research and clinical care services for children with catastrophic diseases. The hospital provides treatment programs such as brain tumors, leukemia, infectious diseases, immunodeficiency diseas …
  • Blue Label Telecoms Ltd (BLU):企業の財務・戦略的SWOT分析
    Blue Label Telecoms Ltd (BLU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • OncoSec Medical Inc (ONCS):医療機器:M&Aディール及び事業提携情報
    Summary OncoSec Medical Inc (OncoSec) is a biotechnology company that offers services to stimulate body’s immune system and attack cancer. It’s lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through i …
  • Apache Corp (APA):企業の財務・戦略的SWOT分析
    Apache Corp (APA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Vascular Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Vascular Pharmaceuticals Inc (VPI) is a biotechnology company that develops and commercializes therapeutics for the treatment of diabetes associated complications. The company develops pre clinical product candidate, VPI-2690B, for treating diabetic nephropathy. Its lead compound is a humani …
  • Avient Corp (POL):企業の財務・戦略的SWOT分析
    Avient Corp (POL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Glaukos Corp (GKOS):企業の財務・戦略的SWOT分析
    Summary Glaukos Corp (Glaukos) is an ophthalmic medical device company that research and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such …
  • Yanbu National Petrochemicals Co (2290):企業の財務・戦略的SWOT分析
    Summary Yanbu National Petrochemicals Co (YANSAB), a subsidiary of Saudi Basic Industries Corp is a manufacturer and distributor of petrochemical products. The company offers products such as ethylene, linear density polyethylene, polypropylene, butene 1, ethylene glycol, polyethylene, butene 2, MTB …
  • TherOx Inc:医療機器:M&Aディール及び事業提携情報
    Summary TherOx Inc (TherOx) is a medical device company that develops and commercializes SuperSaturated Oxygen (SSO2) therapies for treatment of heart attack. Its SSO2 therapy is designed to ameliorate progressive myocardial necrosis by minimizing microvascular damage in heart attack patients. TherO …
  • VPK Packaging Group NV:企業の戦略・SWOT・財務情報
    VPK Packaging Group NV - Strategy, SWOT and Corporate Finance Report Summary VPK Packaging Group NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • JX Nippon Oil & Energy Corporation-石油・ガス分野:企業M&A・提携分析
    Summary JX Nippon Oil & Energy Corporation (JXNOE) is a downstream refining company. The company refines and markets petroleum and petrochemical products. Its products include petrochemicals, lubricants, optical films, greases, fluids, engine oils, composites, Panaferd-AX, Tow PREPREG, sheet pallet …
  • LKQ Corporation:企業の戦略・SWOT・財務情報
    LKQ Corporation - Strategy, SWOT and Corporate Finance Report Summary LKQ Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Rose Petroleum plc (ROSE):石油・ガス:M&Aディール及び事業提携情報
    Summary Rose Petroleum plc (Rose Petroleum), formerly Vane Minerals plc is an oil and gas company. The company explores and produce oil and gas, silver, gold, copper, and uranium deposits across the US and Mexico. Its oil and gas project is located in Paradox Basin in Utah, the US, which covers over …
  • Immune Design Corp (IMDZ):製薬・医療:M&Aディール及び事業提携情報
    Summary Immune Design Corp (Immune Design) is a clinical-stage immunotherapy company that discovers and develops in vivo immunotherapy treatments to target cancer and other chronic diseases. The company develops its product candidates through its ZVex and GLAAS discovery platforms. Immune Design’s p …
  • Steel Authority of India Ltd:戦略・SWOT・企業財務分析
    Steel Authority of India Ltd - Strategy, SWOT and Corporate Finance Report Summary Steel Authority of India Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • TenneT Holding BV:企業の戦略的SWOT分析
    TenneT Holding BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Kier Group plc:企業の戦略・SWOT・財務分析
    Kier Group plc - Strategy, SWOT and Corporate Finance Report Summary Kier Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • RGC Resources Inc (RGCO):企業の財務・戦略的SWOT分析
    Summary RGC Resources Inc (RGC Resources) is an energy company that distributes natural gas. The company offers home appliances such as gas furnaces, natural gas water heaters, gas dryers and ranges, gas logs and space heaters, gas generators, gas grills and gas lights, among others. It offers natur …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆